Chest
-
Critical CareSESSION TYPE: Slide PresentationsPRESENTED ON: Monday, March 24, 2014 at 10:45 AM - 11:45 AMPURPOSE: Patients with severe alcohol withdrawal often require escalating doses of benzodiazepines and intubation with mechanical ventilation which leads to prolonged Intensive Care Unit(ICU) stays. Earlier studies suggest dexmedetomidine is effective in reducing benzodiazepine dosage and autonomic symptoms seen with alcohol withdrawal. We report a retrospective analysis of 53 ICU patients treated for alcohol withdrawal, conducted to compare treatment with benzodiazepine alone to those receiving dexmedetomidine as escalation or substitution therapy. ⋯ The following authors have nothing to disclose: Amit Kachalia, Kinjal Kachalia, Shivaraj Nagalli, Habibur Rahman, Ricardo Lopez, Vincent RizzoNo Product/Research Disclosure Information.
-
Late Breaking AbstractsSESSION TYPE: Slide PresentationPRESENTED ON: Saturday, March 22, 2014 at 09:00 AM - 10:00 AMPURPOSE: Human immunodeficiency virus seropositivity (HIV+) has been considered a contraindication to lung transplantation (LT) primarily due to potential risks of iatrogenic immunosuppression. With the recent passage of the HIV Organ Policy Equity (HOPE) Act on November 21, 2013, the donation of HIV+ organs for transplant in HIV+ recipients is now legal in the USA. As a result there may be an increase in donors for HIV+ recipients. However, there remains only one fully published case report of LT in an HIV+ patient, limiting the evidence base with which to guide medical decision making. We report 3 HIV+ patients at two different medical centers who underwent LT. ⋯ The following authors have nothing to disclose: Ryan Kern, Harish Seethamraju, Paul Blanc, Neeraj Sinha, Matthias Loebe, Jeffrey Golden, Jasleen Kukreja, Scott Scheinin, Steve Hays, Kleinhenz Mary Ellen, Leard Lorri, Charles Hoopes, Jonathan SingerNo Product/Research Disclosure Information.
-
COPD PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Treatment guidelines for chronic obstructive pulmonary disease (COPD) recommend combination therapy of 2 or more long-acting bronchodilators with different mechanisms of action. Here we report the long-term safety of a fixed-dose combination of aclidinium bromide, a long-acting muscarinic antagonist indicated for maintenance treatment of COPD-associated bronchospasm, with formoterol fumarate, a long-acting β2-agonist, in patients with COPD. ⋯ Barry Make: Consultant fee, speaker bureau, advisory committee, etc.: Barry Make received payment for service on the advisory boards of Forest Pharmaceuticals, AstraZeneca, Novartis, Merck, Boehringer Ingelheim, Pfizer, Ikaria, and GlaxoSmithKline, consulting fees from Astellas Pharma, and Talecris Biotherapeutics, lecture fees from GlaxoSmithKline, Boehringer Ingelheim, Pfizer, and Forest Pharmaceuticals, payment for video presentation preparation from Boehringer Ingelheim and Pfizer, payment for document reviews from Spiration., Grant monies (from industry related sources): Barry Make received grant support from AstraZeneca, GlaxoSmithKline, Pfizer, Nabi Biopharmaceuticals, Boehringer Ingelheim, Forest, and Sunovion, Grant monies (from sources other than industry): Barry Make received grant support from the National Heart Lung, and Blood Institute, James Donohue: Consultant fee, speaker bureau, advisory committee, etc.: Dr. Donohue has received consultant/speaker/advisory fees from Novartis, GlaxoSmithKline, Boehringer-Ingelheim, Forest and Pfizer Xiaoyun Zhong: Employee: X. Zhong is an employee of Forest Research Institute, Inc. Anne Leselbaum: Employee: Anne Leselbaum is an employee of Almirall S.A. Cynthia Caracta: Employee: Cynthia Caracta is an employee of Forest Research Institute, Inc., Shareholder: Cynthia Caracta is is a stockowner and has received stock options from Forest Laboratories, Inc.Aclidinium bromide (Tudorzo/Pressair, Eklira/Genuair, Breo/Ellipta) is approved for the maintenance treatment of COPD-associated bronchspasm. The fixed-dose combination of aclidinium bromide/formoterol fumarate is being developed, but not yet approved, for its commercial use for the treatment of COPD.
-
Transplantation PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Share our experience in pediatric lung transplantation, survival rates and analyze the results in comparison to worldwide experience. ⋯ The following authors have nothing to disclose: José González García, Sebastian Peñafiel, Eugenia Libreros Niño, Diana Baquero Velandia, Carlos Jordá Aragón, Victor Calvo Medina, Gabriel Sales Badia, Juan Escrivá, Ángel García Zarza, Juan Pastor GuillemNo Product/Research Disclosure Information.
-
COPD QVA149 PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: The current GOLD strategy recommends combining two long-acting bronchodilators for the maintenance treatment of patients with moderate-to-severe COPD. The SHINE study evaluated the effect of QVA149, a dual bronchodilator combining the LABA indacaterol and the LAMA glycopyrronium (NVA237), compared with glycopyrronium, indacaterol, tiotropium monotherapies and placebo. ⋯ Kenneth Chapman: Consultant fee, speaker bureau, advisory committee, etc.: "KRC holds the GSK-CIHR Research Chair in Respiratory Healthcare Delivery at the University Health Network, has served as a consultant to CSL Behring, GlaxoSmithKline, Novartis, Nycomed (Takeda), and Talecris (Grifols), and has received payment for lectures or service on speakers bureaus from Boehringer-Ingelheim, GlaxoSmithKline, Grifols, Nycomed (Takeda), Family Physicians Airways Group of Canada, Canadian Network for Respiratory Care, and Talecris. " Eric Bateman: Consultant fee, speaker bureau, advisory committee, etc.: Prof Eric Bateman has served on advisory boards for Boehringer Ingelheim, AstraZeneca, Elevation Pharma, Napp Pharma, Novartis, Almirall, Forest, and Merck and Takeda; has served as a consultant to Navigant Consulting, IMS consulting group, ALK-Abello, Almirall, Hoffman la Roche, and ICON; has been paid lecture fees by AstraZeneca, ALK-Abello, Chiesi, Boehringer Ingelheim, GlaxoSmithKline, Nycomed/Takeda, Novartis, Pfizer, and Indegene Lifesciences Ltd. Nicola Gallagher: Employee: Novartis employee Huilin Hu: Employee: Novartis employee Donald Banerji: Employee: Novartis employeeClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA149 is in the late stage phase 3 trials prior to approval.